Arrowhead to Webcast Analyst Day Presentation on Hepatitis B Candidate ARC-520

Home/Newsroom/

Arrowhead to Webcast Analyst Day...

PASADENA, Calif.–(BUSINESS WIRE)–

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical

company developing targeted RNAi therapeutics, today announced that it

will host an analyst day in New York on September 24, 2015, with a

presentation starting at 11:00 a.m. EDT to discuss ARC-520, its

candidate for the treatment of chronic hepatitis B infection. During the

event, Arrowhead management and a panel of key opinion leaders will

discuss results of the Heparc-2001 Phase 2a study and results of a

nonclinical study conducted in 9 chimpanzees chronically infected with

hepatitis B virus.

Guest speakers at the event include:

Robert G. Gish, M.D.
Medical Director, Hepatitis B Foundation
Clinical

Professor of Medicine, University of Nevada, Las Vegas
Senior

Medical Director, St. Joseph’s Hospital and Medical Center
Clinical

Professor of Medicine (Consultant), Stanford Hospital and Medical Center

Stephen A. Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)
Head

of Research and Molecular Development, Victorian Infectious Diseases

Reference Laboratory
Director of WHO Collaborating Centre for Virus

Reference and Research

Robert E. Lanford, PhD
Director of Southwest National

Primate Research Center (SNPRC)
Scientist, Virology and Immunology

and SNPRC, Texas BioMedical Research Institute

A live and archived version of the webcast, including presentation

slides, will be available on the events section of the Company’s website

at ir.arrowheadresearch.com/events.cfm.

To access an audio only version of the live presentation, dial

855-215-6159 toll-free from the U.S. or 315-625-6887 for international

callers and enter Conference ID 19541930.

About ARC-520

Arrowhead’s RNAi-based candidate ARC-520 is being investigated in the

treatment of chronic HBV infection. The small interfering RNAs (siRNAs)

in ARC-520 intervene at the mRNA level, upstream of the reverse

transcription process where current standard of care nucleotide and

nucleoside analogues act. Arrowhead is investigating ARC-520

specifically, to determine if it can be used to achieve a functional

cure, which is an immune clearant state characterized by hepatitis B

s-antigen negative serum with or without sero-conversion. Arrowhead has

completed a Phase 1 single ascending dose study in normal volunteers and

the company is conducting single dose Phase 2a studies and multiple dose

Phase 2b studies in chronic HBV patients. Approximately 350-400 million

people worldwide are chronically infected with the hepatitis B virus,

which can lead to cirrhosis of the liver and is responsible for 80% of

primary liver cancers globally.

About Arrowhead Research Corporation

Arrowhead Research Corporation is a biopharmaceutical company developing

targeted RNAi therapeutics. The company is leveraging its proprietary

Dynamic Polyconjugate™ delivery platform to develop targeted

drugs based on the RNA interference mechanism that efficiently silences

disease-causing genes. Arrowhead’s pipeline includes ARC-520 for chronic

hepatitis B virus, ARC-AAT for liver disease associated with Alpha-1

antitrypsin deficiency, and ARC-F12 for hereditary angioedema and

thromboembolic diseases.

For more information please visit http://www.arrowheadresearch.com,

or follow us on Twitter @ArrowRes.

To be added to the Company’s email list and receive news directly,

please visit http://ir.arrowheadresearch.com/alerts.cfm.

Safe Harbor Statement under the Private Securities Litigation Reform

Act:

This news release contains forward-looking statements within the

meaning of the “safe harbor” provisions of the Private Securities

Litigation Reform Act of 1995. These statements are based upon our

current expectations and speak only as of the date hereof. Our actual

results may differ materially and adversely from those expressed in any

forward-looking statements as a result of various factors and

uncertainties, including our ability to finance our operations, the

future success of our scientific studies, our ability to successfully

develop drug candidates, the timing for starting and completing clinical

trials, rapid technological change in our markets, and the enforcement

of our intellectual property rights. Arrowhead Research Corporation’s

most recent Annual Report on Form 10-K and subsequent Quarterly Reports

on Form 10-Q discuss some of the important risk factors that may affect

our business, results of operations and financial condition. We assume

no obligation to update or revise forward-looking statements to reflect

new events or circumstances.

DYNAMIC POLYCONJUGATES is a trademark of Arrowhead Research

Corporation.

Source: Arrowhead Research Corporation

Arrowhead Research Corporation
Vince Anzalone, CFA
626-304-3400
ir@arrowres.com
or
Investor

Relations:
The Trout Group
Chad Rubin
646-378-2947
ir@arrowres.com
or
Media:
Russo

Partners
Matt Middleman, M.D.
212-845-4272
matt.middleman@russopartnersllc.com

Source: Arrowhead Research Corporation

News Provided by Acquire Media